Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

ClinicalTrials.gov ID: NCT02981472

Public ClinicalTrials.gov record NCT02981472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist or LMWH in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

Study identification

NCT ID
NCT02981472
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
192 participants

Conditions and interventions

Eligibility (public fields only)

Age range
28 Days to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 18, 2017
Primary completion
Oct 17, 2021
Completion
Oct 17, 2021
Last update posted
Oct 2, 2022

2017 – 2021

United States locations

U.S. sites
14
U.S. states
14
U.S. cities
14
Facility City State ZIP Site status
Phoenix Children'S Hospital Phoenix Arizona 85016
University Of California San Diego La Jolla California 92093-0641
Children'S Hospital Colorado Aurora Colorado 80045
Childrens Healthcare Of Atlanta Atlanta Georgia 30322
Local Institution - 0008 Indianapolis Indiana 46202
Local Institution - 0009 Boston Massachusetts 02115
Local Institution - 0013 Ann Arbor Michigan 48109
Childrens Mercy Hospital Kansas City Missouri 64108
Local Institution - 0006 Cincinnati Ohio 45229
Childrens Hospital Of Philadelphia Philadelphia Pennsylvania 19104
Local Institution - 0012 Charleston South Carolina 29425
Local Institution - 0011 Houston Texas 77030-2399
Primary Children's Hospital Salt Lake City Utah 84113
Local Institution - 0055 Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02981472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 2, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02981472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →